You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
SensiTrak: Automated Assessment of Forelimb Sensation
SBC: VULINTUS, INC Topic: NINDSProject Abstract Current common methods for measuring somatosensory function in preclinical rodent models generally rely on withdrawal responses to uncomfortable or painful stimuli. These tests can be stressful to the animal, while also yielding a high variability in measured responses, and repetitive testing in longitudinal models may even result in chronic pain states. To better understand the c ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
SBC: NEUREXIS THERAPEUTICS, INC. Topic: NINDSProject Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we w ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis
SBC: THERAPYX, INC. Topic: 300Abstract This SBIR Phase IIb proposal builds on the success of our Fast-track award supporting the pre-clinical development of FAPXIL, an oral sustained-release micro-particulate formulation of Interleukin-10 for the treatment of Familial Adenomatous Polyposis (FAP). The Phase I portion of our Fast-track project provided validation of our large-batch methods and activity in a clinically-relevant m ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
BoostPrime, A Novel Digital Therapeutic for Craving Mitigation in OUD
SBC: NXTECH INC Topic: NIDAPROJECT SUMMARY The National Institute on Drug Abuse indicates that “there are more deaths, illness, and disabilities from substance use than from any other preventable health condition.” In SUDs, and particularly opioid use disorder (OUD), individuals frequently experience uncontrolled craving symptoms, even receiving treatment under a supervised medication for OUD program (MOUD, also known a ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an AI-empowered device that utilizes multimodal data-visualization to aid in the diagnosis, and treatment, of OUD
SBC: WAVi Co. Topic: NIDAAbstract Assessing the effectiveness of opioid use disorder (OUD), where high relapse rates create financial and social tolls, is a pressing clinical problem in need of better measurement tools. The ability to identify cognitive changes should improve outcomes but current intake into rehabilitation programs doesn’t typically include cognitive tests. Simple, quick, cost-effective, and objective m ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials
SBC: CANGET BIOTEKPHARMA, LLC Topic: 102Abstract/Summary The goals of this SBIR Phase I grant are: (1) to use the clinically compatible FL118 product to perform the non- good laboratory practice (GLP) and GLP toxicology (TOX) and toxicokinetics (TK) studies; and (2) to author and file the FL118 Investigational New Drug (IND) application with the FDA for first-in-human FL118 phase 1 clinical trials in patients with advanced pancreatic du ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Topical Drug Delivery System as an Anti-Inflammatory and Pro-Angiogenic Therapy for Diabetic Wound Healing
SBC: GELSANA THERAPEUTICS INC Topic: 200SUMMARY Impaired wound healing in diabetic patients represents a major clinical problem, resulting in prolonged hospitalizations and significant healthcare expenditures. The financial burden of this is extreme, representing $78 billion annually in the U.S. alone. Two-thirds of all non-traumatic amputations are preceded by a diabetic wound, and every 20 seconds a lower limb is lost to a diabetic wo ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
USE OF DYRK1A/B KINASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
SBC: Avanti Biosciences Inc Topic: 300PROJECT SUMMARYNonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. One-fourth of the adult population suffers from NAFLD worldwide. Nonalcoholic steatohepatitis (NASH), the aggressive form of NAFLD, can progress to cirrhosis and hepatocellular cancer (HCC) and is rapidly becoming the leading cause of end-stage liver disease and liver transplantation. Liver fibrosi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients
SBC: Allander Biotechnologies Topic: NIDCRSummary Oral mucositis, a severe oral ulceration, is a common toxic effect of radio- or chemoradio-therapy (RT or CRT) and a limiting factor to using the optimal dose of radiation for effective cancer treatment. Intensity modulated RT (IMRT) and stereotactic Body RT (SBRT) spare more normal tissues and lessen chronic side effects, but not oral mucosa in head and neck cancer patients. To date, Pali ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Mission Empower
SBC: ROCK BY ROCK LLC Topic: NIGMSProject Summary: Mission Empower: Health According to the Society of Public Health Education, only 7.5% of K-5 schools nationally provide sufficient health education (Society for Public Health Education, 2017). IDM and game-based learning strategies have the potential to help close this gap but, to date, most public health solutions have not been scalable (Zamboni, et al 2019). Too often IDM and h ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health